TD Asset Management
PRME icon

TD Asset Management’s Prime Medicine PRME Stock Holding History

TD Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Hold
94,148
– – ﹤0.01% 1196
2026
Q1 		$328K Hold
94,148
– – ﹤0.01% 1197
2025
Q4 		$327K Sell
94,148
-86,900
-48% -$387K ﹤0.01% 1198
2025
Q3 		$1M Buy
181,048
+158,138
+690% +$642K ﹤0.01% 1090
2025
Q2 		$56.6K Sell
22,910
-23,524
-51% -$36.3K ﹤0.01% 1188
2025
Q1 		$92.4K Hold
46,434
– – ﹤0.01% 1210
2024
Q4 		$136K Hold
46,434
– – ﹤0.01% 1236
2024
Q3 		$161K Hold
46,434
– – ﹤0.01% 1372
2024
Q2 		$239K Sell
46,434
-82,588
-64% -$501K ﹤0.01% 1331
2024
Q1 		$903K Buy
129,022
+76,280
+145% +$578K ﹤0.01% 1182
2023
Q4 		$467K Sell
52,742
-51,800
-50% -$399K ﹤0.01% 1310
2023
Q3 		$997K Buy
104,542
+37,471
+56% +$487K ﹤0.01% 1142
2023
Q2 		$983K Buy
67,071
+43,149
+180% +$602K ﹤0.01% 1137
2023
Q1 		$294K Hold
23,922
– – ﹤0.01% 1345
2022
Q4 		$444K Buy
+23,922
New +$432K ﹤0.01% 1304

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TD Asset Management's PRME Position: Q2 2026 in Review

TD Asset Management held its Prime Medicine (PRME) position steady in Q2 2026 at 94,148 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

TD Asset Management first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $1M in Q3 2025. 123 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • TD Asset Management held 94,148 shares of Prime Medicine worth $347K as of Q2 2026.
  • TD Asset Management left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1196 holding.
  • TD Asset Management first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • TD Asset Management's Prime Medicine position peaked at $1M in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.